Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK 1120212

Known as: GSK-1120212, GSK1120212, MEK Inhibitor GSK1120212 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for… Expand
  • table 1
  • table 2
Highly Cited
2014
Highly Cited
2014
Purpose: MAPK and PI3K/AKT/mTOR pathways play important roles in many tumors. In this study, safety, antitumor activity, and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2013
Highly Cited
2013
PURPOSE BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this… Expand
Highly Cited
2012
Highly Cited
2012
Recent results from clinical trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2012
Highly Cited
2012
Purpose: Activating Q209L/P mutations in GNAQ or GNA11 (GNAQ/11) are present in approximately 80% of uveal melanomas. Mutant GNAQ… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 6
Highly Cited
2011
Highly Cited
2011
Purpose: Despite their preclinical promise, previous MEK inhibitors have shown little benefit for patients. This likely reflects… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2011
Highly Cited
2011
The MEK1 and MEK2 inhibitor GSK1120212 is currently in phase II/III clinical development. To identify predictive biomarkers… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Highly Cited
2011
Highly Cited
2011
CRA8503 Background: In preclinical models, the BRAF/MEK inhibitor (i) combination GSK436/GSK212 has demonstrated enhanced… Expand
Highly Cited
2011
Highly Cited
2011
The MAPK pathway is one of the most important pathways for novel anticancer drug development. We performed high-throughput… Expand
  • table I
Highly Cited
2010
Highly Cited
2010
2503 Background: GSK1120212 is a potent and selective allosteric inhibitor of MEK1/2. The objectives of this study are to define… Expand